A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.

Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms GRANITE-2; RADPAC
  • Most Recent Events

    • 12 Sep 2017 Results assessing paclitaxel with and without everolimus [RAD001] in the second-line treatment of gastric or esophagogastric junction carcinoma, presented at the 42nd European Society for Medical Oncology Congress.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top